Cargando…

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengdi, Qiao, Wenliang, Jiang, Yuting, Zhu, Min, Shao, Jun, Wang, Tao, Liu, Dan, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028135/
https://www.ncbi.nlm.nih.gov/pubmed/31693178
http://dx.doi.org/10.1002/jcp.29371
_version_ 1783498965767946240
author Wang, Chengdi
Qiao, Wenliang
Jiang, Yuting
Zhu, Min
Shao, Jun
Wang, Tao
Liu, Dan
Li, Weimin
author_facet Wang, Chengdi
Qiao, Wenliang
Jiang, Yuting
Zhu, Min
Shao, Jun
Wang, Tao
Liu, Dan
Li, Weimin
author_sort Wang, Chengdi
collection PubMed
description BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC), but it remains unanswered which is superior. The current study aimed to estimate the comparative efficacy and safety of ICI‐chemotherapy versus ICI‐monotherapy in advanced NSCLC. METHODS: Studies were identified by searching PubMed, Embase, and Cochrane library. The randomized controlled trials (RCTs) that ICI monotherapy or ICI plus chemotherapy compared with chemotherapy in NSCLC were included with available primary endpoints of progression‐free survival (PFS), overall survival (OS), objective response rate, or treatment‐related adverse events. A fixed‐effect or random‐effects model was adopted depending on between‐study heterogeneity. RESULTS: A total of 20 RCTs involving 12,025 patients with NSCLC were included. Both ICI‐monotherapy and ICI‐chemotherapy resulted in significantly prolonged survival compared to chemotherapy and the former led to significantly longer PFS. The magnitude of survival benefits appeared to be greatest among those treated with pembrolizumab plus platinum‐based chemotherapy (OS, 0.56; PFS, 0.54). Additionally, OS and PFS advantages of ICI therapies were observed in patients with NSCLC with low or high programmed cell death 1 ligand 1 (PD‐L1) expression level, but not in intermediate PD‐L1 TPS. CONCLUSIONS: Pembrolizumab plus platinum‐based chemotherapy was recommended as the optimal first‐line therapy for advanced patients with NSCLC. Additionally, PD‐L1 alone is not recommended as an adequate molecular biomarker to identify eligible patients for routine clinical practice in immunotherapy.
format Online
Article
Text
id pubmed-7028135
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70281352020-02-25 The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis Wang, Chengdi Qiao, Wenliang Jiang, Yuting Zhu, Min Shao, Jun Wang, Tao Liu, Dan Li, Weimin J Cell Physiol Original Research Articles BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC), but it remains unanswered which is superior. The current study aimed to estimate the comparative efficacy and safety of ICI‐chemotherapy versus ICI‐monotherapy in advanced NSCLC. METHODS: Studies were identified by searching PubMed, Embase, and Cochrane library. The randomized controlled trials (RCTs) that ICI monotherapy or ICI plus chemotherapy compared with chemotherapy in NSCLC were included with available primary endpoints of progression‐free survival (PFS), overall survival (OS), objective response rate, or treatment‐related adverse events. A fixed‐effect or random‐effects model was adopted depending on between‐study heterogeneity. RESULTS: A total of 20 RCTs involving 12,025 patients with NSCLC were included. Both ICI‐monotherapy and ICI‐chemotherapy resulted in significantly prolonged survival compared to chemotherapy and the former led to significantly longer PFS. The magnitude of survival benefits appeared to be greatest among those treated with pembrolizumab plus platinum‐based chemotherapy (OS, 0.56; PFS, 0.54). Additionally, OS and PFS advantages of ICI therapies were observed in patients with NSCLC with low or high programmed cell death 1 ligand 1 (PD‐L1) expression level, but not in intermediate PD‐L1 TPS. CONCLUSIONS: Pembrolizumab plus platinum‐based chemotherapy was recommended as the optimal first‐line therapy for advanced patients with NSCLC. Additionally, PD‐L1 alone is not recommended as an adequate molecular biomarker to identify eligible patients for routine clinical practice in immunotherapy. John Wiley and Sons Inc. 2019-11-06 2020-05 /pmc/articles/PMC7028135/ /pubmed/31693178 http://dx.doi.org/10.1002/jcp.29371 Text en © 2019 The Authors. Journal of Cellular Physiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Articles
Wang, Chengdi
Qiao, Wenliang
Jiang, Yuting
Zhu, Min
Shao, Jun
Wang, Tao
Liu, Dan
Li, Weimin
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
title The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
title_full The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
title_fullStr The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
title_full_unstemmed The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
title_short The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
title_sort landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: a systematic review and meta‐analysis
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028135/
https://www.ncbi.nlm.nih.gov/pubmed/31693178
http://dx.doi.org/10.1002/jcp.29371
work_keys_str_mv AT wangchengdi thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT qiaowenliang thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT jiangyuting thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT zhumin thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT shaojun thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT wangtao thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT liudan thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT liweimin thelandscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT wangchengdi landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT qiaowenliang landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT jiangyuting landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT zhumin landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT shaojun landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT wangtao landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT liudan landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis
AT liweimin landscapeofimmunecheckpointinhibitorpluschemotherapyversusimmunotherapyforadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis